
The Wait Is Over: 8 Adalimumab Biosimilars Launching in the US in July
After 7 years, competition for Humira is here. The first adalimumab biosimilar launched in January, but an additional 8, including an interchangeable product, will hit the US market in July.
The wait for adalimumab
For nearly 6 months there has only been 1 adalimumab biosimilar available on the US market, but in July the competition is going to ramp up with 8 additional biosimilars poised to launch (Table).
Interchangeable Biosimilars
However, 1 of the 8 set to hit the US market in July will have an advantage: Cyltezo (adalimumab-adbm) from Boehringer Ingelheim is currently the only adalimumab biosimilar with interchangeability.
The product was first approved in October 2021 as the
While Cyltezo is currently the only interchangeable adalimumab biosimilar, there may be more to come as Hadlima and Abrilada will likely be submitted to the FDA to receive the designation. In addition, AVT02, from Alvotech, is under review with the FDA for both approval and interchangeability. However, AVT02’s approval has been delayed with
Interchangeability has been a source of controversy in the United States. It is a regulatory designation given by the FDA to biosimilars that have gone through switching trials, which cost the manufacturers additional time and money. However,
The interchangeability designation is unique to the United States; in comparison, European countries consider any biosimilar automatically interchangeable.
When a biosimilar has the interchangeability designation in the United States, pharmacists can switch out the prescribed reference product for the biosimilar without needing the physicians’ permission, depending on state laws. While every state has
Formulary Decisions
Optum Rx, the pharmacy benefit manager (PBM) of UnitedHealth Group, just recently announced that it was
“As an industry leader driving competition and biosimilar access, we are bringing unprecedented choice and value in this highly utilized but historically very expensive drug class,” Heather Cianfrocco, CEO, Optum Rx, said in a statement.8 “PBMs have a responsibility to leverage competition to lower cost and create choice. Access to new biosimilars and their available list price options provides physicians, clients, and patients with affordable treatment options.”
Earlier in June, SmithRx announced it was making Yusimry available for
References
1. Walker J, Gorenstein D. AbbVie’s blockbuster drug Humira finally loses its 20-year, $200 billion monopoly. NPR. January 31, 2023. Accessed June 28, 2023.
2. Dunleavy K. The top 20 drugs by worldwide sales in 2021. FiercePharma. May 31, 2022. Accessed June 28, 2023.
3. FDA approves Cyltezo, the first interchangeable biosimilar to Humira. News release. October 18, 2021. Accessed June 28, 2023.
4. FDA approves first interchangeable biosimilar insulin product for treatment of diabetes. News release. July 28, 2021. Accessed June 28, 2023.
5. Jeremias S. FDA issues another CRL for Alvotech’s adalimumab biosimilar. The Center for Biosimilars®. April 14, 2023. Accessed June 29, 2023.
6. Jeremias S. What's holding up biosimilar uptake? Misconceptions, misaligned incentives, panelists say. The Center for Biosimilars. January 26, 2022. Accessed June 29, 2023.
7. Jeremias S. The age of adalimumab is upon us: How stakeholders can prepare. The Center for Biosimilars. June 28, 2023. Accessed June 29, 2023.
8. Optum Rx expands choice, improves affordability for patients with two additional Humira biosimilars. News release. June 23, 2023. Accessed June 29, 2023.
9. Myshko D. OptumRx to cover Amgen’s biosimilar of Humira. Formulary Watch®. November 17, 2022. Accessed June 29, 2023.
10. Joszt L. SmithRx to offer adalimumab biosimilar Yusimry at 90% discount to Humira. The American Journal of Managed Care. June 14, 2023. Accessed June 29, 2023.
11. Joszt L. PBMs announce 2023 coverage plans for adalimumab biosimilars. AJMC.com. January 1, 2023. Accessed June 13, 2023.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.